Overcoming cellular multidrug resistance using classical nanomedicine formulations

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F12%3A00372588" target="_blank" >RIV/61389013:_____/12:00372588 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.ejps.2011.08.028" target="_blank" >http://dx.doi.org/10.1016/j.ejps.2011.08.028</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejps.2011.08.028" target="_blank" >10.1016/j.ejps.2011.08.028</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Overcoming cellular multidrug resistance using classical nanomedicine formulations

Popis výsledku v původním jazyce

In the present report, we have set out to evaluate the ability of classical (and pharmacologically inactive) carrier materials to overcome MDR. To this end, four different drug-sensitive and drug-resistant cancer cell lines were treated with increasing concentrations of free doxorubicin, of polymer-bound doxorubicin, of micellar doxorubicin and of liposomal doxorubicin, and resistance indices (IC50 in resistant cells/IC50 in sensitive cells) were determined. In addition, the cellular uptake of the fourformulations was evaluated using fluorescence microscopy. It was found that the carrier materials did manage to overcome MDR to some extent, but that the overall benefit was quite small; only for polymer-bound doxorubicin in A431 cells, a significant (4-fold) reduction in the resistance index was observed. These findings indicate that the ability of classical nanomedicines to overcome cellular MDR should not be overestimated.

Název v anglickém jazyce

Overcoming cellular multidrug resistance using classical nanomedicine formulations

Popis výsledku anglicky

In the present report, we have set out to evaluate the ability of classical (and pharmacologically inactive) carrier materials to overcome MDR. To this end, four different drug-sensitive and drug-resistant cancer cell lines were treated with increasing concentrations of free doxorubicin, of polymer-bound doxorubicin, of micellar doxorubicin and of liposomal doxorubicin, and resistance indices (IC50 in resistant cells/IC50 in sensitive cells) were determined. In addition, the cellular uptake of the fourformulations was evaluated using fluorescence microscopy. It was found that the carrier materials did manage to overcome MDR to some extent, but that the overall benefit was quite small; only for polymer-bound doxorubicin in A431 cells, a significant (4-fold) reduction in the resistance index was observed. These findings indicate that the ability of classical nanomedicines to overcome cellular MDR should not be overestimated.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

CD - Makromolekulární chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/IAA400500806" target="_blank" >IAA400500806: Větvené a hypervětvené polymerní nosiče léčiv pro lokální terapii</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Pharmaceutical Sciences

ISSN

0928-0987

e-ISSN

—

Svazek periodika

45

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

421-428

Kód UT WoS článku

000300861700005

EID výsledku v databázi Scopus

—